Genetic Signatures’ CEO Dr John Melki was recently interviewed by Nadine Blayney from AusBiz about the Company’s unique 3base® technology, its advantages for detecting infectious diseases, the development pipeline, revenue sources, and plans for further investment and expansion in key international markets.

Channel 9 interviews our customer SydPath, taking a look at their increased testing capabilities in response to the COVID-19 outbreak in NSW, implementing our high-throughput testing technology for respiratory infection

Genetic Signatures’ CEO- Dr. John Melki speaking at ASX Small and Mid-Cap Conference held in Sydney Australia September 2018